Personal information

Activities

Collapse all

Employment (3)

Neurommune Therapeutics Inc: Boston, MA, US

2025-01 to present | CEO (Management)
Employment
Source: Self-asserted source
Robert Spencer

New Hope Scientific: New Hope, PA, US

2024-07 to 2025-01 | Principal
Employment
Source: Self-asserted source
Robert Spencer

Cara Therapeutics Inc: Stamford, CT, US

2006-06 to 2024-06 | Vice President (Research & Development)
Employment
Source: Self-asserted source
Robert Spencer

Works (2)

Assessment of the physical dependence potential of difelikefalin: Randomized placebo‐controlled study in patients receiving hemodialysis

Clinical and Translational Science
2023-09 | Journal article
DOI: 10.1111/cts.13538
Contributors: Robert H. Spencer; Catherine Munera; Megan J. Shram; Frédérique Menzaghi
Source: check_circle
Crossref

Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis

Clinical Pharmacokinetics
2023-09 | Journal article
DOI: 10.1007/s40262-023-01262-2
Contributors: Jeffrey G. Stark; Patrick K. Noonan; Robert H. Spencer; Sarbani Bhaduri; Stephen J. O’Connor; Frédérique Menzaghi
Source: check_circle
Crossref
How many people are using ORCID?